AstraZeneca
  • Bookmark This Page
  • Print This Page
  • Share with a Friend
Change Text Size
Change Text Size
Change Text Size
Change Text Size
Change Text Size

What do your patients’ caregivers want to know?

Sometimes your patients’ caregivers may feel embarrassed about what they don’t know about asthma—especially if their child has been diagnosed for a while. To help you understand their educational needs and challenges, we’ve compiled the answers to the most commonly visited poll questions from the PULMICORT RESPULES consumer Web site.

Below are answers to the most commonly visited poll questions from the consumer Web site for PULMICORT RESPULES

Table: Length of Asthma TreatmentTable: Reasons for Skipping TreatmentTable: Asthma SeverityTable: Child's CaregiversTable: Opinion on Outgrowing AsthmaTable: Most Common Asthma SymptomsTable: Last ER VisitTable: Controller Medication Use

“Next” Button
Learn about patient support programs

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information (PDF).]